open access

Vol 14, No 3 (2020)
Review paper
Published online: 2020-08-19
Get Citation

The role of pregabalin in neuropathic pain management in cancer patients

Piotr Jakubow, Urszula Kościuczuk, Juliusz Kosel, Piotr Soroko, Julia Kondracka, Mariola Tałałaj
DOI: 10.5603/PMPI.2020.0020
·
Palliat Med Pract 2020;14(3):175-182.

open access

Vol 14, No 3 (2020)
Review articles
Published online: 2020-08-19

Abstract

Despite the wide availability of analgesics for prescription in cancer pain, including both opioid and non-opioid
medications, population studies have for many years demonstrated unadvisable pain management.
International analyses indicate inadequate use of opioid and adjuvant drugs per capita. At the same time,
patients complain about the accompanying pain, not treated effectively, especially in the course of cancer.
One of the many causes of cancer pain that is difficult to treat is the co-occurrence of neuropathic pain.
The article presents contemporary views on the treatment of neuropathic pain associated with cancer,
including the site of application of gabapentinoids in the treatment scheme.

Abstract

Despite the wide availability of analgesics for prescription in cancer pain, including both opioid and non-opioid
medications, population studies have for many years demonstrated unadvisable pain management.
International analyses indicate inadequate use of opioid and adjuvant drugs per capita. At the same time,
patients complain about the accompanying pain, not treated effectively, especially in the course of cancer.
One of the many causes of cancer pain that is difficult to treat is the co-occurrence of neuropathic pain.
The article presents contemporary views on the treatment of neuropathic pain associated with cancer,
including the site of application of gabapentinoids in the treatment scheme.

Get Citation

Keywords

cancer pain, neuropathic pain, pharmacotherapy, gabapentinoids, gabapentin, pregabalin

About this article
Title

The role of pregabalin in neuropathic pain management in cancer patients

Journal

Palliative Medicine in Practice

Issue

Vol 14, No 3 (2020)

Article type

Review paper

Pages

175-182

Published online

2020-08-19

DOI

10.5603/PMPI.2020.0020

Bibliographic record

Palliat Med Pract 2020;14(3):175-182.

Keywords

cancer pain
neuropathic pain
pharmacotherapy
gabapentinoids
gabapentin
pregabalin

Authors

Piotr Jakubow
Urszula Kościuczuk
Juliusz Kosel
Piotr Soroko
Julia Kondracka
Mariola Tałałaj

References (52)
  1. Caraceni A, Hanks G, Kaasa S, et al. Use of opioid analgesics in the treatment of cancer pain: evidence-based recommendations from the EAPC. The Lancet Oncology. 2012; 13(2): e58–e68.
  2. Edwards HL, Mulvey MR, Bennett MI. Cancer-Related Neuropathic Pain. Cancers (Basel). 2019; 11(3).
  3. Arias-Casais N, Garralda E, Rhee JY, De Li, Pons JJ, Clark D. EAPC Atlas of palliative care in Europe 2019. Vilvoorde: EAPC Press 2019.
  4. Ciałkowska-Rysz A, Dzierżanowski T. Podstawowe zasady farmakoterapii bólu u chorych na nowotwory i inne przewlekłe, postępujące, zagrażające życiu choroby. PalliativeMedicine. 2014; 1: 1–6.
  5. Dzierżanowski T, Ciałkowska-Rysz A. Ból neuropatyczny u pacjentów objętych opieką paliatywną. Med Paliat. 2010; 2: 57–66.
  6. Leppert W. Rola analgetyków opioidowych w leczeniu bólu neuropatycznego u chorych na nowotwory. Medycyna Paliat Prakt. 2014; 8(2): 81–84.
  7. Zajączkowska R, Wordliczek J, Leppert W. Mechanizmy i zespoły bólu neuropatycznego u chorych na nowotwór. Med Paliat Prakt. 2014; 8(2): 66–73.
  8. Sumitani M, Sakai T, Matsuda Y, et al. Executive summary of the Clinical Guidelines of Pharmacotherapy for Neuropathic Pain: second edition by the Japanese Society of Pain Clinicians. J Anesth. 2018; 32(3): 463–478.
  9. Finnerup NB, Attal N, Haroutounian S, et al. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14(2): 162–173.
  10. Baron R, Maier C, Attal N, et al. Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain. 2017; 158(2): 261–272.
  11. Janecki M. Przegląd narzędzi służących do oceny bólu neuropatycznego. Med Paliat Prakt. 2014; 8(2): 74–77.
  12. Mathieson S, Maher CG, Terwee CB, et al. Neuropathic pain screening questionnaires have limited measurement properties. A systematic review. J Clin Epidemiol. 2015; 68(8): 957–966.
  13. Boland EG, Mulvey MR, Bennett MI. Classification of neuropathic pain in cancer patients. Curr Opin Support Palliat Care. 2015; 9(2): 112–115.
  14. Chaparro LE, Wiffen PJ, Moore RA, et al. Combination pharmacotherapy for the treatment of neuropathic pain in adults. Cochrane Database Syst Rev. 2012(7): CD008943.
  15. Szczudlik A, Dobrogowski J, Wordliczek J, et al. Diagnosis and Management of Neuropathic Pain: Review of Literature and Recommendations of the Polish Association for the Study of Pain and the Polish Neurological Society – Part One. Ból. 2014; 15(3): 8–21.
  16. Szczudlik A, et al. Rozpoznanie i leczenie bólu neuropatycznego część 2: przegląd piśmiennictwa i zalecenia Polskiego Towarzystwa Badania Bólu i Towarzystwa Neurologicznego. Ból 2014; 15(2): 8–18. PTBB. (www.ptbb.pl).
  17. Ciałkowska-Rysz A, Dzierżanowski T. Topical morphine for treatment of cancer-related painful mucosal and cutaneous lesions: a double-blind, placebo-controlled cross-over clinical trial. Arch Med Sci. 2019; 15(1): 146–151.
  18. Wordliczek J, Zajączkowska R, Leppert W. Pharmacotherapy of neuropathic pain. Med Paliat Prakt. 2017; 11(2): 61–73.
  19. Ciałkowska-Rysz A, Dzierżanowski T. Ból neuropatyczny u pacjenta z naciekiem nowotworowym okolicy lędźwiowo-krzyżowej – opis przypadku. Med Paliat. 2012; 4: 229–231.
  20. Moulin D, Boulanger A, Clark AJ, et al. Canadian Pain Society. Pharmacological management of chronic neuropathic pain: revised consensus statement from the Canadian Pain Society. Pain Res Manag. 2014; 19(6): 328–335.
  21. Fallon M, Giusti R, Aielli F, et al. ESMO Guidelines Committee. Electronic address: clinicalguidelines@esmo.org, ESMO Guidelines Committee. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. Ann Oncol. 2018; 29(Suppl 4): iv166–iv191.
  22. Rayment C, Hjermstad MJ, Aass N, et al. European Palliative Care Research Collaborative (EPCRC). Neuropathic cancer pain: prevalence, severity, analgesics and impact from the European Palliative Care Research Collaborative-Computerised Symptom Assessment study. Palliat Med. 2013; 27(8): 714–721.
  23. Attal N. Neuropathic Pain Special Interest Group of the International Association for the Study of Pain. Management of neuropathic cancer pain. Ann Oncol. 2010; 21(5): 1134–1135.
  24. Oosterling A, te Boveldt N, Verhagen C, et al. Neuropathic Pain Components in Patients with Cancer: Prevalence, Treatment, and Interference with Daily Activities. Pain Pract. 2016; 16(4): 413–421.
  25. Bennett MI, Kaasa S, Barke A, et al. IASP Taskforce for the Classification of Chronic Pain. The IASP classification of chronic pain for ICD-11: chronic cancer-related pain. Pain. 2019; 160(1): 38–44.
  26. Finnerup NB, Haroutounian S, Kamerman P, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016; 157(8): 1599–1606.
  27. The International Classification of Diseases, Tenth Revision, Clinical Modification. 2020 edition of ICD–10–CM, American Medical Association 2020. https://www.cdc.gov/nchs/icd/icd10cm.htm. (The 2020 edition of ICD–10–CM became effective on 1 October 2019).
  28. Scholz J, Finnerup NB, Attal N, et al. Classification Committee of the Neuropathic Pain Special Interest Group (NeuPSIG). The IASP classification of chronic pain for ICD-11: chronic neuropathic pain. Pain. 2019; 160(1): 53–59.
  29. Bennett MI, Kaasa S, Barke A, et al. IASP Taskforce for the Classification of Chronic Pain. The IASP classification of chronic pain for ICD-11: chronic cancer-related pain. Pain. 2019; 160(1): 38–44.
  30. Finnerup NB, Sindrup SH, Jensen TS. The evidence for pharmacological treatment of neuropathic pain. Pain. 2010; 150(3): 573–581.
  31. Yoon SoY, Oh J. Neuropathic cancer pain: prevalence, pathophysiology, and management. Korean J Intern Med. 2018; 33(6): 1058–1069.
  32. Mercadante S, Klepstad P, Kurita GP, et al. European Palliative Care Research Collaborative (EPCRC). Sympathetic blocks for visceral cancer pain management: A systematic review and EAPC recommendations. Crit Rev Oncol Hematol. 2015; 96(3): 577–583.
  33. Colloca L, Ludman T, Bouhassira D, et al. Neuropathic pain. Nat Rev Dis Primers. 2017; 3: 17002.
  34. Kane CM, Mulvey MR, Wright S, et al. Opioids combined with antidepressants or antiepileptic drugs for cancer pain: Systematic review and meta-analysis. Palliat Med. 2018; 32(1): 276–286.
  35. Woroń J, Adamczyk A, Malec-Milewska M, et al. Stosowanie koanalgetyków u pacjentów z bólem neuropatycznym w przebiegu choroby nowotworowej. Med Paliat Prakt 2014; 8. 2014; 8(2): 85–90.
  36. Kotlinska-Lemieszek A, Klepstad P, Haugen DF. Clinically significant drug-drug interactions involving opioid analgesics used for pain treatment in patients with cancer: a systematic review. Drug Des Devel Ther. 2015; 9: 5255–5267.
  37. Mercadante S, Caruselli A, Casuccio A. The use of ketamine in a palliative-supportive care unit: a retrospective analysis. Ann Palliat Med. 2018; 7(2): 205–210.
  38. Uchitel OD, Di Guilmi MN, Urbano FJ, et al. Acute modulation of calcium currents and synaptic transmission by gabapentinoids. Channels (Austin). 2010; 4(6): 490–496.
  39. Jordan RI, Mulvey MR, Bennett MI. A critical appraisal of gabapentinoids for pain in cancer patients. Curr Opin Support Palliat Care. 2018; 12(2): 108–117.
  40. Slee A, Nazareth I, Bondaronek P, et al. Pharmacological treatments for generalised anxiety disorder: a systematic review and network meta-analysis. Lancet. 2019; 393(10173): 768–777.
  41. Wordliczek J, Kotlińska-Lemieszek A, Leppert W, et al. Farmakoterapia bólu u chorych na nowotwory – zalecenia Polskiego Towarzystwa Badania Bólu, Polskiego Towarzystwa Medycyny Paliatywnej, Polskiego Towarzystwa Onkologicznego, Polskiego Towarzystwa Medycyny Rodzinnej i Polskiego Towarzystwa Anestezjologii i Intensywnej Terapii. Pain. 2017; 18(3): 11–53.
  42. Andruszkiewicz R, Silverman RB. 4-Amino-3-alkylbutanoic acids as substrates for gamma-aminobutyric acid aminotransferase. J Biol Chem. 1990; 265(36): 22288–22291.
  43. Linde M, Mulleners W, Chronicle E, et al. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults. Cochrane Database of Systematic Reviews. 2013; 6(6): CD010609.
  44. Bennett MI, Laird B, van Litsenburg C, et al. Pregabalin for the management of neuropathic pain in adults with cancer: a systematic review of the literature. Pain Med. 2013; 14(11): 1681–1688.
  45. Bockbrader HN, Wesche D, Miller R, et al. A comparison of the pharmacokinetics and pharmacodynamics of pregabalin and gabapentin. Clin Pharmacokinet. 2010; 49(10): 661–669.
  46. Frampton JE. Pregabalin: a review of its use in adults with generalized anxiety disorder. CNS Drugs. 2014; 28(9): 835–854.
  47. Wensel TM, Powe KW, Cates ME. Pregabalin for the treatment of generalized anxiety disorder. Ann Pharmacother. 2012; 46(3): 424–429.
  48. Derry S, Bell RF, Straube S, et al. Pregabalin for neuropathic pain in adults. Cochrane Database Syst Rev. 2019; 1: CD007076.
  49. Onakpoya IJ, Thomas ET, Lee JJ, et al. Benefits and harms of pregabalin in the management of neuropathic pain: a rapid review and meta-analysis of randomised clinical trials. BMJ Open. 2019; 9(1): e023600.
  50. de Andrade DC, Jacobsen Teixeira M, Galhardoni R, et al. PreOx Workgroup. Pregabalin for the Prevention of Oxaliplatin-Induced Painful Neuropathy: A Randomized, Double-Blind Trial. Oncologist. 2017; 22(10): 1154–e105.
  51. Gül ŞK, Tepetam H, Gül HL. Duloxetine and pregabalin in neuropathic pain of lung cancer patients. Brain Behav. 2020; 10(3): e01527.
  52. Yajima R, Matsumoto K, Ise Y, et al. Pregabalin prescription for terminally ill cancer patients receiving specialist palliative care in an acute hospital. J Pharm Health Care Sci. 2016; 2: 29.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Czasopismo Medycyna Paliatywna w Praktyce dostęne jest również w Ikamed - księgarnia medyczna

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl